Literature DB >> 26233189

Phase-based vascular input function: Improved quantitative DCE-MRI of atherosclerotic plaques.

R H M van Hoof1, E Hermeling1, M T B Truijman2, R J van Oostenbrugge3, J W H Daemen4, R J van der Geest5, N P van Orshoven6, A H Schreuder7, W H Backes8, M J A P Daemen9, J E Wildberger1, M E Kooi1.   

Abstract

PURPOSE: Quantitative pharmacokinetic modeling of dynamic contrast-enhanced (DCE)-MRI can be used to assess atherosclerotic plaque microvasculature, which is an important marker of plaque vulnerability. Purpose of the present study was (1) to compare magnitude- versus phase-based vascular input functions (m-VIF vs ph-VIF) used in pharmacokinetic modeling and (2) to perform model calculations and flow phantom experiments to gain more insight into the differences between m-VIF and ph-VIF.
METHODS: Population averaged m-VIF and ph-VIFs were acquired from 11 patients with carotid plaques and used for pharmacokinetic analysis in another 17 patients. Simulations, using the Bloch equations and the MRI scan geometry, and flow phantom experiments were performed to determine the effect of local blood velocity on the magnitude and phase signal enhancement.
RESULTS: Simulations and flow phantom experiments revealed that flow within the lumen can lead to severe underestimation of m-VIF, while this is not the case for the ph-VIF. In line, the peak concentration of the m-VIF is significantly lower than ph-VIF (p < 0.001), in vivo. Quantitative model parameters for m- and ph-VIF differed in absolute values but were moderate to strongly correlated with each other [K(trans) Spearman's ρ > 0.93 (p < 0.001) and vp Spearman's ρ > 0.58 (p < 0.05)].
CONCLUSIONS: m-VIF is strongly influenced by local blood velocity, which leads to underestimation of the contrast medium concentration. Therefore, it is advised to use ph-VIF for DCE-MRI analysis of carotid plaques for accurate quantification.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26233189     DOI: 10.1118/1.4924949

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  5 in total

1.  Ischemic Stroke Patients Demonstrate Increased Carotid Plaque Microvasculature Compared to (Ocular) Transient Ischemic Attack Patients.

Authors:  Raf H M van Hoof; Floris H B M Schreuder; Patty Nelemans; Martine T B Truijman; Narender P van Orshoven; Tobien H Schreuder; Werner H Mess; Sylvia Heeneman; Robert J van Oostenbrugge; Joachim E Wildberger; M Eline Kooi
Journal:  Cerebrovasc Dis       Date:  2017-09-26       Impact factor: 2.762

Review 2.  Dynamic Contrast-Enhanced MRI to Study Atherosclerotic Plaque Microvasculature.

Authors:  Raf H M van Hoof; Sylvia Heeneman; Joachim E Wildberger; M Eline Kooi
Journal:  Curr Atheroscler Rep       Date:  2016-06       Impact factor: 5.113

Review 3.  Vessel wall characterization using quantitative MRI: what's in a number?

Authors:  Bram F Coolen; Claudia Calcagno; Pim van Ooij; Zahi A Fayad; Gustav J Strijkers; Aart J Nederveen
Journal:  MAGMA       Date:  2017-08-14       Impact factor: 2.310

4.  Symptomatic Carotid Plaques Demonstrate Less Leaky Plaque Microvasculature Compared With the Contralateral Side: A Dynamic Contrast-Enhanced Magnetic Resonance Imaging Study.

Authors:  Geneviève A J C Crombag; Raf H M van Hoof; Robert J Holtackers; Floris H B M Schreuder; Martine T B Truijman; Tobien A H C M L Schreuder; Narender P van Orshoven; Werner H Mess; Paul A M Hofman; Robert J van Oostenbrugge; Joachim E Wildberger; M Eline Kooi
Journal:  J Am Heart Assoc       Date:  2019-04-16       Impact factor: 5.501

5.  Microvasculature and intraplaque hemorrhage in atherosclerotic carotid lesions: a cardiovascular magnetic resonance imaging study.

Authors:  Geneviève A J C Crombag; Floris H B M Schreuder; Raf H M van Hoof; Martine T B Truijman; Nicky J A Wijnen; Stefan A Vöö; Patty J Nelemans; Sylvia Heeneman; Paul J Nederkoorn; Jan-Willem H Daemen; Mat J A P Daemen; Werner H Mess; J E Wildberger; Robert J van Oostenbrugge; M Eline Kooi
Journal:  J Cardiovasc Magn Reson       Date:  2019-03-04       Impact factor: 5.364

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.